WASHINGTON— Federal health regulators have approved a second vaccine to prevent a strain of bacteria that can cause deadly cases of meningitis. The Food and Drug Administration said it cleared Novartis' Bexsero vaccine against a subtype of meningococcal bacteria in people ages 10 to 25. The agency cleared a similar vaccine from Pfizer last October.» Read More
In my less than five weeks on Twitter, I've gotten ideas for four blogs and late yesterday, for the first time, I got a legit news tip off a tweet (for the uninitiated, that's what the short messages sent on Twitter are called.)
Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.
Dendreon is up yet again today on heavy volume. Several investors have emailed me and one analyst voicemailed me asking if I know what's going on. I don't. And I see no news.
Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.
Drug names are a favorite topic of mine. So, can someone please explain why the proposed commercial name for Eli Lilly's new bloodthinner in the U.S. is "Effient" with two f's, but in the UK, where the pill is making its debut today, it's going by "Efient" with only one f?
The emails flew over my post yesterday about the big pharma slides I saw on a flight last week.
China announced Monday the outlines of a thorough reform of the health care system that pledges to provide improved services to all citizens by 2020, tackling a critical issue that has become a major source of public dissatisfaction.
I don't want to get anyone in trouble, so I won't name the company, the drug or even what it's for. (Note to corporate PR folks reading this: Don't even try to pry it out of me. My lips are sealed.) All I'll say is that it's one of the biggies.
I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon story.
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
A prestigious peer-reviewed journal is proposing taking a hardline stance on what it calls the "pervasive" funding relationship between drug and medical device companies and professional medical associations.
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.
There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.
I'm on the road on assignment, but used a little downtime to go through the "Pharma's Market" mailbox. Regarding my farewell to Genentech post yesterday a couple of folks emailed to point out that GENE was Genentech's ticker symbol when it was traded on the Nasdaq back in the day. Then it was GNE on the NYSE before going to the much better DNA.
DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.
Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.
All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.
Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.